BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 19567772)

  • 1. Valacyclovir-induced psychosis and manic symptoms in an adolescent young woman with genital herpes simplex.
    Aslam SP; Carroll KA; Naz B; Alao AO
    Psychosomatics; 2009; 50(3):293-6. PubMed ID: 19567772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-day, patient-initiated famciclovir therapy versus 3-day valacyclovir regimen for recurrent genital herpes: a randomized, double-blind, comparative trial.
    Abudalu M; Tyring S; Koltun W; Bodsworth N; Hamed K
    Clin Infect Dis; 2008 Sep; 47(5):651-8. PubMed ID: 18637755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Valacyclovir for the treatment of genital herpes.
    Brantley JS; Hicks L; Sra K; Tyring SK
    Expert Rev Anti Infect Ther; 2006 Jun; 4(3):367-76. PubMed ID: 16771614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. The Valaciclovir International Study Group.
    Tyring SK; Douglas JM; Corey L; Spruance SL; Esmann J
    Arch Dermatol; 1998 Feb; 134(2):185-91. PubMed ID: 9487210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding.
    Wald A; Selke S; Warren T; Aoki FY; Sacks S; Diaz-Mitoma F; Corey L
    Sex Transm Dis; 2006 Sep; 33(9):529-33. PubMed ID: 16540883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of valacyclovir on viral shedding in immunocompetent patients with recurrent herpes simplex virus 2 genital herpes: a US-based randomized, double-blind, placebo-controlled clinical trial.
    Fife KH; Warren TJ; Ferrera RD; Young DG; Justus SE; Heitman CK; Burroughs SM
    Mayo Clin Proc; 2006 Oct; 81(10):1321-7. PubMed ID: 17036557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An international, randomized, double-blind, placebo-controlled, study of valacyclovir for the suppression of herpes simplex virus type 2 genital herpes in newly diagnosed patients.
    Fife KH; Warren TJ; Justus SE; Heitman CK;
    Sex Transm Dis; 2008 Jul; 35(7):668-73. PubMed ID: 18461016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of valacyclovir for the suppression and episodic treatment of herpes simplex virus in patients with HIV.
    Warren T; Harris J; Brennan CA
    Clin Infect Dis; 2004 Nov; 39 Suppl 5():S258-66. PubMed ID: 15494897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valacyclovir. New indication: for genital herpes, simpler administration.
    Can Fam Physician; 1999 Jul; 45():1698-700, 1703-5. PubMed ID: 10424269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment.
    Leone PA; Trottier S; Miller JM
    Clin Infect Dis; 2002 Apr; 34(7):958-62. PubMed ID: 11880962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valacyclovir in the treatment of genital herpes and herpes zoster.
    Baker DA
    Expert Opin Pharmacother; 2002 Jan; 3(1):51-8. PubMed ID: 11772333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-day regimen of valacyclovir for treatment of recurrent genital herpes simplex virus 2 infection.
    Bavaro JB; Drolette L; Koelle DM; Almekinder J; Warren T; Tyring S; Wald A
    Sex Transm Dis; 2008 Apr; 35(4):383-6. PubMed ID: 18362859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valacyclovir prophylaxis to prevent recurrent herpes at delivery: a randomized clinical trial.
    Sheffield JS; Hill JB; Hollier LM; Laibl VR; Roberts SW; Sanchez PJ; Wendel GD
    Obstet Gynecol; 2006 Jul; 108(1):141-7. PubMed ID: 16816068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interventions for men and women with their first episode of genital herpes.
    Heslop R; Roberts H; Flower D; Jordan V
    Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD010684. PubMed ID: 27575957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppressive therapy with valacyclovir in early genital herpes: a pilot study of clinical efficacy and herpes-related quality of life.
    Handsfield HH; Warren T; Werner M; Phillips JA
    Sex Transm Dis; 2007 Jun; 34(6):339-43. PubMed ID: 17065847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of daily valacyclovir suppression on herpes simplex virus type 2 viral shedding in HSV-2 seropositive subjects without a history of genital herpes.
    Sperling RS; Fife KH; Warren TJ; Dix LP; Brennan CA
    Sex Transm Dis; 2008 Mar; 35(3):286-90. PubMed ID: 18157071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond efficacy: new issues for HSV antiviral therapy.
    Wald A
    Genitourin Med; 1997 Apr; 73(2):83-4. PubMed ID: 9215085
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of safety and efficacy of prolonged suppressive therapy of genital herpes with valacyclovir.
    Durglishvili N; Shishniashvili D; Kvirkvelia V
    Georgian Med News; 2009; (172-173):47-9. PubMed ID: 19644189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects.
    Pasternak B; Hviid A
    JAMA; 2010 Aug; 304(8):859-66. PubMed ID: 20736469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects.
    DeJesus E; Wald A; Warren T; Schacker TW; Trottier S; Shahmanesh M; Hill JL; Brennan CA;
    J Infect Dis; 2003 Oct; 188(7):1009-16. PubMed ID: 14513421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.